Aptamer specifically targeting inflammatory synoviocytes in rheumatoid arthritis and its application

Abstract

The invention relates to the field of biotechnology, and provides an aptamer specifically targeting to inflammatory synovial cells of human rheumatoid arthritis (RA), wherein the aptamer has a nucleotide sequence shown as SEQ ID NO.1. The invention further provides applications of the aptamer in preparing a biological probe for identifying the inflammatory synovial cells and applications of the aptamer in preparing medicines or medicine carriers for resisting rheumatoid arthritis in a targeting manner. The aptamer has high selectivity for the inflammatory synovial cells, and the combination with hepatic cells is eliminated or weakened. The biological probe containing the aptamer can identify in-vitro human inflammatory synovial cells, such as the inflammatory synovial cells in a synovial tissue slice of an RA patient, and thus a basis is provided for the clinical diagnosis and targeting therapy of RA.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a single-stranded DNA aptamer specifically targeting human rheumatoid arthritis inflammatory synoviocytes and an application thereof. Background technique [0002] Rheumatoid Arthritis (Rheumatoid Arthritis, RA) is a chronic systemic autoimmune disease characterized by multi-joint synovial inflammatory lesions, known as "the number one disabling disease", and is called immortal cancer by the world medical community , has become one of the four chronic diseases threatening human health in the 21st century. RA has a high incidence in adults, with an incidence rate of about 20-40% per 100,000 adult population. Studies have shown that 10% of RA patients experience severe dysfunction within 2 years of onset, and about 50% of patients lose their ability to work after 10 years of illness. At present, the annual per capita disease cost of RA patients in my country is 13,506 RMB, accounting...

AI Technical Summary

Problems solved by technology

[0005] However, so far, no reports have been found on the successful application of SELEX screening technology to the development of diagnostic reagents and therapeutic drugs for rheumatoid arthritis.

Images